Interim results were in line with the 28 October trading update, reflecting the impact of the pandemic, with sales down 27% and LBITDA of £1.3m. However, c.10% LFL growth for Health & Nutrition (HN) in October and November is encouraging and points to long-term growth. Together with confirmation that first shipments against the initial 1m order for AbC-19 rapid antibody tests have taken place as well as first shipments of VISITECT CD4 Advanced Diseases tests to Africa, we expect a strong H2 (c.7 ....
30 Nov 2020
Omega Diagnostics - FY 2021 interims – three key value drivers
Omega Diagnostics Group PLC (ODX:LON) | 57.0 0.3 0.9% | Mkt Cap: 102.6m
-
-
-
Mark Brewer | Arshad Ahad
-
12 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - FY 2021 interims – three key value drivers
Omega Diagnostics Group PLC (ODX:LON) | 57.0 0.3 0.9% | Mkt Cap: 102.6m
- Published:
30 Nov 2020 -
Author:
Mark Brewer | Arshad Ahad -
Pages:
12 -
Interim results were in line with the 28 October trading update, reflecting the impact of the pandemic, with sales down 27% and LBITDA of £1.3m. However, c.10% LFL growth for Health & Nutrition (HN) in October and November is encouraging and points to long-term growth. Together with confirmation that first shipments against the initial 1m order for AbC-19 rapid antibody tests have taken place as well as first shipments of VISITECT CD4 Advanced Diseases tests to Africa, we expect a strong H2 (c.7 ....